Stephen K. Brannan, MD
a:1:{i:0;s:60:"Medical Affairs, Bristol Myers Squibb, Princeton, New Jersey";}
Original Research
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
February 26, 2025
In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic...
